Botulinum toxin in high-risk BPH patients in retention

Sreedhar Reddy, Arun Chawla, Joseph Thomas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This is a prospective study evaluating the efficacy of botulinum toxin A injection in benign prostatic hyperplasia (BPH) patients. Twenty-one men with benign prostatic enlargement on chronic indwelling catheter for at least 3 months who were not candidates for surgery because of poor general condition received 200 U botulinum toxin A in the transition zone by transrectal approach under ultrasound guidance. This was done as an outpatient procedure without any anesthesia. Mean patient age was 80 ± 2 years. No significant local effects occurred. Patients were reevaluated at 1 and 3 months post-treatment. Baseline prostate volume of 70 ± 10 ml decreased to 57 ± 10 ml at 1 month and to 47 ± 7 ml at 3 months. At 1 month, 16 patients (76%) could resume voiding with a mean Qmax OF 9.0 ± 1.2 ml/s. At 3 months, 17 patients (81%) voided with a mean Qmax of 10.3 ± 1.4 ml/s. Residual urine was 80 ± 19 ml and 92 ± 24 ml at 1 and 3 months, respectively. Mean serum total PSA decreased from 6.0 ± 1.1 ng/ml at baseline to 5.0 ± 0.9 ng/ml at 3 months. The authors conclude that botulinum A injection into the prostate swiftly reduces prostate volume and may be a promising treatment for refractory urinary retention in patients with benign prostatic enlargement who are unfit for surgery.

Original languageEnglish
Number of pages1
JournalIndian Journal of Urology
Volume24
Issue number2
Publication statusPublished - 01-07-2008

Fingerprint

Botulinum Toxins
Prostatic Hyperplasia
Prostate
Type A Botulinum Toxins
Injections
Indwelling Catheters
Urinary Retention
Outpatients
Anesthesia
Urine
Prospective Studies
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Reddy, Sreedhar ; Chawla, Arun ; Thomas, Joseph. / Botulinum toxin in high-risk BPH patients in retention. In: Indian Journal of Urology. 2008 ; Vol. 24, No. 2.
@article{340ffe1e56b14253ab00b750eb709ba4,
title = "Botulinum toxin in high-risk BPH patients in retention",
abstract = "This is a prospective study evaluating the efficacy of botulinum toxin A injection in benign prostatic hyperplasia (BPH) patients. Twenty-one men with benign prostatic enlargement on chronic indwelling catheter for at least 3 months who were not candidates for surgery because of poor general condition received 200 U botulinum toxin A in the transition zone by transrectal approach under ultrasound guidance. This was done as an outpatient procedure without any anesthesia. Mean patient age was 80 ± 2 years. No significant local effects occurred. Patients were reevaluated at 1 and 3 months post-treatment. Baseline prostate volume of 70 ± 10 ml decreased to 57 ± 10 ml at 1 month and to 47 ± 7 ml at 3 months. At 1 month, 16 patients (76{\%}) could resume voiding with a mean Qmax OF 9.0 ± 1.2 ml/s. At 3 months, 17 patients (81{\%}) voided with a mean Qmax of 10.3 ± 1.4 ml/s. Residual urine was 80 ± 19 ml and 92 ± 24 ml at 1 and 3 months, respectively. Mean serum total PSA decreased from 6.0 ± 1.1 ng/ml at baseline to 5.0 ± 0.9 ng/ml at 3 months. The authors conclude that botulinum A injection into the prostate swiftly reduces prostate volume and may be a promising treatment for refractory urinary retention in patients with benign prostatic enlargement who are unfit for surgery.",
author = "Sreedhar Reddy and Arun Chawla and Joseph Thomas",
year = "2008",
month = "7",
day = "1",
language = "English",
volume = "24",
journal = "Indian Journal of Urology",
issn = "0970-1591",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

Botulinum toxin in high-risk BPH patients in retention. / Reddy, Sreedhar; Chawla, Arun; Thomas, Joseph.

In: Indian Journal of Urology, Vol. 24, No. 2, 01.07.2008.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Botulinum toxin in high-risk BPH patients in retention

AU - Reddy, Sreedhar

AU - Chawla, Arun

AU - Thomas, Joseph

PY - 2008/7/1

Y1 - 2008/7/1

N2 - This is a prospective study evaluating the efficacy of botulinum toxin A injection in benign prostatic hyperplasia (BPH) patients. Twenty-one men with benign prostatic enlargement on chronic indwelling catheter for at least 3 months who were not candidates for surgery because of poor general condition received 200 U botulinum toxin A in the transition zone by transrectal approach under ultrasound guidance. This was done as an outpatient procedure without any anesthesia. Mean patient age was 80 ± 2 years. No significant local effects occurred. Patients were reevaluated at 1 and 3 months post-treatment. Baseline prostate volume of 70 ± 10 ml decreased to 57 ± 10 ml at 1 month and to 47 ± 7 ml at 3 months. At 1 month, 16 patients (76%) could resume voiding with a mean Qmax OF 9.0 ± 1.2 ml/s. At 3 months, 17 patients (81%) voided with a mean Qmax of 10.3 ± 1.4 ml/s. Residual urine was 80 ± 19 ml and 92 ± 24 ml at 1 and 3 months, respectively. Mean serum total PSA decreased from 6.0 ± 1.1 ng/ml at baseline to 5.0 ± 0.9 ng/ml at 3 months. The authors conclude that botulinum A injection into the prostate swiftly reduces prostate volume and may be a promising treatment for refractory urinary retention in patients with benign prostatic enlargement who are unfit for surgery.

AB - This is a prospective study evaluating the efficacy of botulinum toxin A injection in benign prostatic hyperplasia (BPH) patients. Twenty-one men with benign prostatic enlargement on chronic indwelling catheter for at least 3 months who were not candidates for surgery because of poor general condition received 200 U botulinum toxin A in the transition zone by transrectal approach under ultrasound guidance. This was done as an outpatient procedure without any anesthesia. Mean patient age was 80 ± 2 years. No significant local effects occurred. Patients were reevaluated at 1 and 3 months post-treatment. Baseline prostate volume of 70 ± 10 ml decreased to 57 ± 10 ml at 1 month and to 47 ± 7 ml at 3 months. At 1 month, 16 patients (76%) could resume voiding with a mean Qmax OF 9.0 ± 1.2 ml/s. At 3 months, 17 patients (81%) voided with a mean Qmax of 10.3 ± 1.4 ml/s. Residual urine was 80 ± 19 ml and 92 ± 24 ml at 1 and 3 months, respectively. Mean serum total PSA decreased from 6.0 ± 1.1 ng/ml at baseline to 5.0 ± 0.9 ng/ml at 3 months. The authors conclude that botulinum A injection into the prostate swiftly reduces prostate volume and may be a promising treatment for refractory urinary retention in patients with benign prostatic enlargement who are unfit for surgery.

UR - http://www.scopus.com/inward/record.url?scp=43149115659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149115659&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:43149115659

VL - 24

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 2

ER -